Skip to main content

LLY

Stock

LLY

Stock
Health Care
Drug Manufacturers - General

Performance overview

LLY Price
Price Chart

Forward-looking statistics

Beta
0.59
Risk
31.58%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees41K
Market cap$807.8B

Fundamentals

Enterprise value$735.3B
Revenue$49.0B
Revenue per employee
Profit margin22.67%
Debt to equity243.61

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$12.26
Dividend per share$6.00
Revenue per share$54.44
Avg trading volume (30 day)$3B
Avg trading volume (10 day)$3B
Put-call ratio

Macro factor sensitivity

Growth+1.3
Credit+0.2
Liquidity-0.4
Inflation-1.3
Commodities+0.4
Interest Rates-0.2

Valuation

Dividend yield0.77%
PEG Ratio34.45
Price to sales14.30
P/E Ratio34.45
Enterprise Value to Revenue15.01
Price to book46.93

Upcoming events

Next earnings dayAugust 7, 2025
Next dividend day
Ex. dividend dayAugust 15, 2025

News

Ally Financial (ALLY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ally Financial (ALLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research (July 11, 2025)
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

Zacks Investment Research (July 11, 2025)
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump

Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.

Zacks Investment Research (July 10, 2025)
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.

Benzinga (July 9, 2025)
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'

President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon."  But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.

CNBC (July 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free